State of Tennessee Treasury Department cut its holdings in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 6.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 49,644 shares of the life sciences company’s stock after selling 3,542 shares during the period. State of Tennessee Treasury Department owned about 0.06% of Integra Lifesciences worth $2,376,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of IART. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Integra Lifesciences by 38.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock valued at $182,000 after purchasing an additional 1,054 shares during the last quarter. Zions Bancorporation bought a new position in Integra Lifesciences during the 3rd quarter valued at about $205,000. Campbell Newman Asset Management Inc. grew its holdings in Integra Lifesciences by 21.5% during the 4th quarter. Campbell Newman Asset Management Inc. now owns 6,964 shares of the life sciences company’s stock valued at $333,000 after purchasing an additional 1,234 shares during the last quarter. Oppenheimer & Co. Inc. grew its holdings in Integra Lifesciences by 25.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 7,293 shares of the life sciences company’s stock valued at $368,000 after purchasing an additional 1,466 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Integra Lifesciences during the 4th quarter valued at about $378,000. Hedge funds and other institutional investors own 90.93% of the company’s stock.
Integra Lifesciences Holdings Corp (NASDAQ IART) traded down $0.18 during trading on Wednesday, reaching $56.05. 388,903 shares of the company’s stock traded hands, compared to its average volume of 514,373. Integra Lifesciences Holdings Corp has a 12 month low of $40.51 and a 12 month high of $57.14. The stock has a market cap of $4,377.62, a PE ratio of 69.34, a price-to-earnings-growth ratio of 1.72 and a beta of 0.65. The company has a debt-to-equity ratio of 1.85, a quick ratio of 1.51 and a current ratio of 2.36.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.08. Integra Lifesciences had a net margin of 5.45% and a return on equity of 16.94%. The firm had revenue of $368.60 million during the quarter, compared to analysts’ expectations of $362.64 million. During the same quarter in the prior year, the company earned $0.52 EPS. The company’s revenue was up 44.2% compared to the same quarter last year. research analysts predict that Integra Lifesciences Holdings Corp will post 2.33 earnings per share for the current year.
IART has been the topic of several analyst reports. TheStreet upgraded shares of Integra Lifesciences from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. Oppenheimer set a $60.00 price target on shares of Integra Lifesciences and gave the company a “buy” rating in a report on Wednesday, February 28th. Jefferies Group reiterated a “buy” rating and set a $63.00 price target on shares of Integra Lifesciences in a report on Thursday, March 1st. Barclays reissued a “hold” rating and issued a $53.00 price objective on shares of Integra Lifesciences in a research report on Tuesday, January 9th. Finally, Zacks Investment Research raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $54.18.
In related news, VP Joseph Vinhais sold 6,800 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $54.13, for a total transaction of $368,084.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christian S. Schade sold 15,658 shares of the business’s stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $52.88, for a total transaction of $827,995.04. Following the transaction, the director now owns 75,262 shares of the company’s stock, valued at approximately $3,979,854.56. The disclosure for this sale can be found here. Insiders sold a total of 70,996 shares of company stock valued at $3,822,267 in the last ninety days. Corporate insiders own 21.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Integra Lifesciences Holdings Corp (IART) Holdings Cut by State of Tennessee Treasury Department” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/03/14/state-of-tennessee-treasury-department-has-2-38-million-position-in-integra-lifesciences-holdings-corp-iart.html.
Integra Lifesciences Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.